BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35617957)

  • 21. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group.
    Huang CC; Gadd S; Breslow N; Cutcliffe C; Sredni ST; Helenowski IB; Dome JS; Grundy PE; Green DM; Fritsch MK; Perlman EJ
    Clin Cancer Res; 2009 Mar; 15(5):1770-8. PubMed ID: 19208794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
    Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
    J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finding the way to Wilms tumor by comparing the primary and relapse tumor samples.
    Spreafico F; Ciceri S; Perotti D
    Cell Rep Med; 2022 Jun; 3(6):100667. PubMed ID: 35732150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutional 560.49 kb chromosome 2p24.3 duplication including the MYCN gene identified by SNP chromosome microarray analysis in a child with multiple congenital anomalies and bilateral Wilms tumor.
    Micale MA; Embrey B; Macknis JK; Harper CE; Aughton DJ
    Eur J Med Genet; 2016 Dec; 59(12):618-623. PubMed ID: 27794475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
    Murphy AJ; Cheng C; Williams J; Shaw TI; Pinto EM; Dieseldorff-Jones K; Brzezinski J; Renfro LA; Tornwall B; Huff V; Hong AL; Mullen EA; Crompton B; Dome JS; Fernandez CV; Geller JI; Ehrlich PF; Mulder H; Oak N; Maciezsek J; Jablonowski CM; Fleming AM; Pichavaram P; Morton CL; Easton J; Nichols KE; Clay MR; Santiago T; Zhang J; Yang J; Zambetti GP; Wang Z; Davidoff AM; Chen X
    Nat Commun; 2023 Dec; 14(1):8006. PubMed ID: 38110397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wilms tumors arising at young age: a genetic basis to distinguish subgroups for individualized therapy.
    Royer-Pokora B; Graf N
    J Clin Oncol; 2011 Jun; 29(16):e485-6; author reply e487-8. PubMed ID: 21519025
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
    Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
    Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome analysis of stage I epithelial-predominant favorable-histology Wilms tumors: A report from Children's Oncology Group study AREN03B2.
    Parsons LN; Mullen EA; Geller JI; Chi YY; Khanna G; Glick RD; Aldrink JH; Vallance KL; Kim Y; Fernandez CV; Dome JS; Perlman EJ
    Cancer; 2020 Jun; 126(12):2866-2871. PubMed ID: 32267967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
    Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
    J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.
    Woods AD; Berlow NE; Ortiz MV; Dela Cruz F; Siddiquee A; Coutinho DF; Purohit R; Freier KET; Michalek JE; Lathara M; Matlock K; Srivivasa G; Royer-Pokora B; Veselska R; Kung AL; Keller C
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29401. PubMed ID: 34693628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wilms tumor genes.
    Huff V; Saunders GF
    Biochim Biophys Acta; 1993 Dec; 1155(3):295-306. PubMed ID: 8268188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse.
    Ciceri S; Montalvão-de-Azevedo R; Tajbakhsh A; Bertolotti A; Spagnuolo RD; Boschetti L; Capasso M; D'Angelo P; Serra A; Diomedi-Camassei F; Meli M; Nantron M; Quarello P; Buccoliero AM; Tamburini A; Ciniselli CM; Verderio P; Collini P; Radice P; Spreafico F; Perotti D
    Cancer Gene Ther; 2021 Sep; 28(9):1016-1024. PubMed ID: 33281191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients.
    Segers H; Kersseboom R; Alders M; Pieters R; Wagner A; van den Heuvel-Eibrink MM
    Eur J Cancer; 2012 Nov; 48(17):3249-56. PubMed ID: 22796116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic and chromosomal alterations in Kenyan Wilms Tumor.
    Lovvorn HN; Pierce J; Libes J; Li B; Wei Q; Correa H; Gouffon J; Clark PE; Axt JR; Hansen E; Newton M; O'Neill JA;
    Genes Chromosomes Cancer; 2015 Nov; 54(11):702-15. PubMed ID: 26274016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gain of MYCN region in a Wilms tumor-derived xenotransplanted cell line.
    Noguera R; Villamón E; Berbegall A; Machado I; Giner F; Tadeo I; Navarro S; Llombart-Bosch A
    Diagn Mol Pathol; 2010 Mar; 19(1):33-9. PubMed ID: 20186010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.